Aventis Articles
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
Stock Commentary - Europe - week to June 1, 2009
4 June 2009
EMEA's CHMP gives nod to six Plavix generics
2 June 2009
Teva launches YouTube channel for PD
29 May 2009
Sanofi settles Medicaid price investigation
29 May 2009
Biotie appoints Chris Piggot CBO
28 May 2009
Retail drug sales in year to March 2009
22 May 2009
P&G wins patent infringement case over Actonel
15 May 2009
FDA accuses Sanofi of using misleading article
15 May 2009
Sanofi to pay up to $315M for Kyowa MAb
15 May 2009
Stock Commentary - Europe - week to may 11, 2009
14 May 2009
FDA licenses Sanofi flu vaccine plant
8 May 2009
Sanofi signs eye disease R&D deal with OBM; returns Trovax rights after pipeline review
30 April 2009
Sanofi loses appeal over Lovenox patent
30 April 2009
Stock Commentary - Europe - week to April 27, 2009
30 April 2009
B-MS' 1st qtr hit by tax and legal costs
29 April 2009
URCH study foresees more pharma mega-mergers
27 April 2009
8%-12% growth for Sanofi Pasteur?
24 April 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Sanofi sees more China opportunities
24 April 2009
Retail drug sales in year to February 2009
24 April 2009
Stock Commentary - Europe - week to April 20, 2009
23 April 2009
Sanofi may have Dengue vacc by 2015
22 April 2009
Sanofi relocates plant to Binjiang
22 April 2009
Sanofi invests $90M in Lantus plant in China
22 April 2009
Japan stock market week to April 20, 2009
21 April 2009
Sanofi launches Apidra SoloSTAR in USA
21 April 2009
Biogen's 1st-qtr profit jumps 54% to $244M
20 April 2009
Pfizer appoints Martine George as VP of medical affairs
16 April 2009
Stock Commentary - New York week to April 13, 2009
16 April 2009
Stock Commentary - Europe - week to April 13, 2009
16 April 2009
Aclasta more effective than risedronate
14 April 2009
Record sales for Sanofi Japan, says president
14 April 2009
BioWa licenses Potelligent tech to Sanofi
9 April 2009
Sanofi launches Aplenzin in USA
9 April 2009
Sanofi confirms buy of Brazil's Medley
9 April 2009
Daiichi/Lilly's Efient gets first world launch in UK - first new antiplatelet drug in a decade
9 April 2009
Stock Commentary - Europe - week to Aug 15
8 April 2009
Sanofi's talks with Piramal "collapse," claim
7 April 2009
B-MS exec pleads guilty to anti-trust dealings
7 April 2009
French pharmacy sales up only 1.8% in 2008
6 April 2009
Sanofi acquires Mexico's Kendick
3 April 2009
Retail drug sales in year to January 2009
3 April 2009
Stock Commentary - Europe - week to mar 30, 2009
2 April 2009
Solvay viewing options for pharma
2 April 2009
Stock Commentary - New York week to March 30, 2009
2 April 2009
B-MS to pay $2.1M settlement to FTC
1 April 2009
Aspirin more effective with Plavix in AF
1 April 2009
GSK and Sanofi vying for Shantha?
31 March 2009
US drug sales growth slows to 1.3%
30 March 2009
Stock Commentary - Europe - week to March 23, 2009
30 March 2009
Retail drug sales in year to December 2008
30 March 2009
AEterna Zentaris' loss up 85% on R&D costs
30 March 2009
Sanofi appoints Paul Chew as US CMO/CSO
23 March 2009
Major US federal switch on medicinal marijuana
23 March 2009
FDA panel gives nod to Sanofi's Multaq
23 March 2009
Bayer drops 10% ahead of rivaroxaban review
23 March 2009
US FDA approves Orexo's Edluar
23 March 2009
Oxford BioMed's 2008 loss narrows 61%
23 March 2009
Lunesta misses Ph II efficacy endpoints
16 March 2009
Genfit and Sanofi extend R&D accord until end of 2010
16 March 2009
Stock Commentary - Europe - week to Mar 9, 2009
16 March 2009
NICE gives nod to Bayer's Xarelto
16 March 2009
Thailand "threat" to USA over CL policy
16 March 2009
Stock Commentary - Europe - week to mar 2, 2009
9 March 2009
Japan stock market week to March 2, 2009
9 March 2009
Sanofi's Apidra SoloSTAR cleared in the USA
9 March 2009
Sanofi's Intanza/IDflu cleared in Europe
9 March 2009
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
